AORT

Artivion's stock price was $25.410 as of May 8, 2026, down 28.26% from its previous closing price. The stock is down 44.29% year-to-date. In Q1 2026, Artivion reported revenues of $116.3 million, an 18% increase year-over-year on a GAAP basis. The company announced the acquisition of Endospan Ltd. for $135 million. Artivion lowered its full-year 2026 revenue guidance to a range of $480 million to $496 million. Analyst actions have been mixed, with a consensus "Moderate Buy" rating and an average price target of $47.83. In the past three months, Artivion insiders have sold $4,977,158.00 in company stock.